Incyte (INCY) stock forecast for 2022. Forecast tables and graphs.

Incyte (INCY) stock forecast for 2022

Last update: June 5, 2023 (06:06)

Sector: Healthcare

The share price of Incyte Corp. (INCY) now

What analysts predict: $82.24
52-week High/Low: $86.29 / $60.71

50/200 Day Moving Average: $69.31 / $74.39

This figure corresponds to the Average Price over the previous 50/200 days. For Incyte stocks, the 50-day moving average is the resistance level today.

For Incyte stocks, the 200-day moving average is the resistance level today.

Are you interested in Incyte stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Incyte stock price in 2022. How much will one Incyte share be worth in 2022? Is it worth taking profit / loss on Incyte stock now or waiting? What are analysts' forecasts for Incyte stock?

We forecast Incyte stock performance using neural networks based on historical data on Incyte stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. The Incyte stock prediction results are shown below and presented as a graph, table and text information.

Incyte stock forecasts are adjusted once a day based on the closing price of the previous trading day.

The minimum target price for Incyte analysts is $82.24.

Today 200 Day Moving Average is the resistance level (74.39 $).

50 Day Moving Average is the resistance level (69.31 $).

Historical and forecast chart of Incyte stock

The chart below shows the historical price of Incyte stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Incyte stock price can be found in the table below.

Incyte (INCY) Forecast for 2022

Month Target Pes. Opt. Vol., %

Incyte information and performance

Incyte Corp is an American pharmaceutical company. The company was founded in Palo Alto, California in 1991 and became famous in 1993. Incyte has one drug, Jakafi, which has been approved by the US Food and Drug Administration (FDA) and has been prescribed to patients in the United States.

Incyte Address


Market Capitalization: 13 951 924 000 $

Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.

EBITDA: 575 701 000 $

EBITDA is earnings before interest, income tax and depreciation of assets.

PE Ratio: 42.26

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: 0.466

Price/earnings to growth


Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.


Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: 1.48

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: -0.427
Quarterly Revenue Growth YOY: 0.103
Trailing PE: 42.26

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 14.95

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 3.896

Enterprise Value (EV) /Revenue

EV To EBITDA: 18.63

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 223088000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Incyte price target for 2022 by month

Related stocks from Healthcare sector


All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.